Dupont Capital Management Corp Jounce Therapeutics, Inc. Transaction History

Dupont Capital Management Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 29, 2021	SELL	$6.73 - $13.87 $234,829 - $483,965	-34,893 Closed	0 $0
Q4 2020 Jan 28, 2021	SELL	$6.37 - $10.33 $16,593 - $26,909	-2,605 Reduced 6.95%	34,893 $244,000
Q3 2020 Oct 29, 2020	BUY	$4.58 - $10.95 $171,740 - $410,603	37,498 New	37,498 $306,000
Q1 2020 Apr 29, 2020	SELL	$2.91 - $8.7 $195,773 - $585,301	-67,276 Closed	0 $0
Q4 2019 Jan 27, 2020	BUY	$2.81 - $9.21 $189,045 - $619,611	67,276 New	67,276 $587,000
Q3 2019 Oct 28, 2019	SELL	$3.33 - $4.93 $215,870 - $319,592	-64,826 Closed	0 $0
Q2 2019 Jul 30, 2019	BUY	$4.3 - $6.73 $278,751 - $436,278	64,826 New	64,826 $321,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.